Veradermics, Incorporated (MANE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Veradermics, Incorporated (MANE) has a cash flow conversion efficiency ratio of -0.054x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-21.17 Million) by net assets ($391.87 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Veradermics, Incorporated defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Veradermics, Incorporated - Cash Flow Conversion Efficiency Trend (2023–2025)
This chart illustrates how Veradermics, Incorporated's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Veradermics, Incorporated Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Veradermics, Incorporated ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Allete Inc
NYSE:ALE
|
0.031x |
|
Trex Company Inc
NYSE:TREX
|
-0.119x |
|
Shanghai Wanye Enterprises Co Ltd
SHG:600641
|
-0.078x |
|
GEPIC Energy Development Co Ltd
SHE:000791
|
0.102x |
|
Tutor Perini Corporation
NYSE:TPC
|
0.116x |
|
FOSITEK CORP
TW:6805
|
0.047x |
|
Wuhan Raycus Fiber Laser Technologies Co Ltd Class A
SHE:300747
|
0.033x |
|
K.P.R. Mill Limited
NSE:KPRMILL
|
0.229x |
Annual Cash Flow Conversion Efficiency for Veradermics, Incorporated (2023–2025)
The table below shows the annual cash flow conversion efficiency of Veradermics, Incorporated from 2023 to 2025. For the full company profile with market capitalisation and key ratios, see MANE stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-121.01 Million | $-71.60 Million | 0.592x | +236.54% |
| 2024-12-31 | $54.66 Million | $-23.69 Million | -0.433x | +53.11% |
| 2023-12-31 | $14.62 Million | $-13.51 Million | -0.924x | -- |
About Veradermics, Incorporated
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in t… Read more